Active ingredient
- dabigatran etexilate mesilate
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
Every patient prescribed Pradaxa will receive a Patient Alert Card in the medication pack. As the card contains important information the patient should be instructed to carry the patient alert card at all times and present it when seeing a health care professional. The patient should be counselled about the need for compliance and signs of bleeding and when to seek medical attention.
This risk minimisation material provides recommendations for the use of Pradaxa for the treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age (paed. VTE) in order to minimise the risk of bleeding. Please ensure you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa in the paediatric population and providing guidance on how to manage that risk. For hard copies please contact our medical information department at 01344 424600 or email: [email protected]
For Healthcare Professionals
This risk minimisation material provides recommendations for the use of Pradaxa in NVAF and DVT/PE in order to minimise the risk of bleeding. Please ensure that you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa and providing guidance on how to manage that risk. For hard copies please contact our medical information department at 01344 424600 or email: [email protected]
For Healthcare Professionals
If you would like to make a comment or send us feedback on this material, click here.
Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
+44 (0)1344 424 600
+44 (0)1344 742579 - Pradaxa enquiries
01344 741444